Shirish Gadgeel, MBBS, FASCO, has been named as the new co-chair of the Protocol Review and Monitoring Committee at Winship Cancer Institute of Emory University.
Shirish Gadgeel, MBBS, FASCO, has been named co-chair of the Protocol Review and Monitoring Committee (PRMC) at Winship Cancer Institute of Emory University. The committee assesses the scientific merit and feasibility of all cancer clinical trials conducted at Winship and monitors enrollment and progress throughout the trial’s duration.
Together with co-chair and Winship pediatric oncologist Tamara Miller, MD, MSCE, Gadgeel will lead the Protocol Review and Monitoring Committee in ensuring rigorous internal oversight of Winship’s cancer clinical trials, a requirement for all National Cancer Institute-designated cancer centers. The committee is composed of faculty members and specialists with diverse scientific and clinical expertise to ensure a critical and fair review of all clinical cancer protocols. It has the authority to activate meritorious trials and to close trials that are not meeting criteria for scientific progress, enrollment or performance standards. The Protocol Review and Monitoring Committee complements the work of Emory University’s Institutional Review Board, which focuses on the protection of patients, and Winship’s Data and Safety Monitoring Committee, which ensures patient safety, ethical research conduct and data integrity.
“We are pleased to welcome Dr. Gadgeel as our new PRMC co-chair,” says Winship Executive Director Suresh S. Ramalingam, MD, FACP, FASCO. “His expertise and leadership will help us continue advancing high‑quality, high‑impact research for the patients and communities we serve.”
A thoracic oncologist, Gadgeel is a professor and vice chair for clinical research in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He has been actively involved in lung cancer clinical trial development and administration for more than 25 years. He has conducted several institutional and cooperative group investigator-initiated clinical trials and served on steering committees for clinical trials that changed the standard of care. He also served on Wayne State University’s Institutional Review Board and on Rogel Cancer Center’s PRMC at the University of Michigan.